KLRS - Kalaris Therapeutics, Inc.

KLRS - Kalaris Therapeutics, Inc.

https://kalaristx.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Kalaris Therapeutics Inc. ( KLRS ) Upgraded to Buy: Here's What You Should Know

Zacks Commentary • 1 week, 6 days ago • score: 0.31

Kalaris Therapeutics Inc. (KLRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Kalaris to Participate at Stifel Ophthalmology Forum - Kalaris Therapeutics ( NASDAQ:KLRS )

Benzinga • 3 months, 3 weeks ago • score: 0.13

PALO ALTO, Calif., May 23, 2025 ( GLOBE NEWSWIRE ) -- Kalaris Therapeutics, Inc. KLRS ( "Kalaris" ) , a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an ...

Kalaris to Participate at Stifel Ophthalmology Forum

GlobeNewswire • 3 months, 3 weeks ago • score: 0.17

PALO ALTO, Calif., May 23, 2025 ( GLOBE NEWSWIRE ) -- Kalaris Therapeutics, Inc. ( Nasdaq: KLRS ) ( "Kalaris" ) , a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. The company is headquartered in Palo Alto, California.

52W High

$24.15

52W Low

$2.14

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.70

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

17.19%

Institutions (25–75% balanced)

70.34%

Shares Outstanding

18,702,400

Float

4,289,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

As of 2025-03-31 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-2.71

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

N/A

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.5544

Previous

0.6359

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025